title: Proglucagon-Derived Peptides Do Not Significantly Affect Acute Exocrine Pancreas in Rats.
abstract: Reports have suggested a link between treatment with glucagon-like peptide 1 (GLP-1) analogs and an increased risk of pancreatitis. Oxyntomodulin, a dual agonist of both GLP-1 and glucagon receptors, is currently being investigated as a potential antiobesity therapy, but little is known about its pancreatic safety. The aim of the study was to investigate the acute effect of oxyntomodulin and other proglucagon-derived peptides on the rat exocrine pancreas.
  
  
  
  Glucagon-like peptide 1, oxyntomodulin, glucagon, and exendin-4 were infused into anesthetized rats to measure plasma amylase concentration changes. In addition, the effect of each peptide on both amylase release and proliferation in rat pancreatic acinar (AR42J) and primary isolated ductal cells was determined.
  
  
  
  Plasma amylase did not increase postpeptide infusion, compared with vehicle and cholecystokinin; however, oxyntomodulin inhibited plasma amylase when coadministered with cholecystokinin. None of the peptides caused a significant increase in proliferation rate or amylase secretion from acinar and ductal cells.
  
  
  
  The investigated peptides do not have an acute effect on the exocrine pancreas with regard to proliferation and plasma amylase, when administered individually. Oxyntomodulin seems to be a potent inhibitor of amylase release, potentially making it a safer antiobesity agent regarding pancreatitis, compared with GLP-1 agonists.
authors.affiliation: From the Sections of *Investigative Medicine and †Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom.
authors.forename: Elina
authors.initials: E
authors.lastname: Akalestou
authors.forename: Ioannis
authors.initials: I
authors.lastname: Christakis
authors.forename: Antonia M
authors.initials: AM
authors.lastname: Solomou
authors.forename: James S
authors.initials: JS
authors.lastname: Minnion
authors.forename: Guy A
authors.initials: GA
authors.lastname: Rutter
authors.forename: Stephen R
authors.initials: SR
authors.lastname: Bloom
mesh_terms: D000199:Actins / Q000235:genetics; D000681:Amylases / Q000097:blood / Q000378:metabolism; D000818:Animals; D045744:Cell Line, Tumor; D002478:Cells, Cultured; D000077270:Exenatide; D015870:Gene Expression; D005934:Glucagon / Q000008:administration & dosage / Q000494:pharmacology; D052216:Glucagon-Like Peptide 1 / Q000008:administration & dosage / Q000494:pharmacology; D007275:Injections, Intravenous; D019394:Ki-67 Antigen / Q000235:genetics; D008297:Male; D053772:Oxyntomodulin / Q000008:administration & dosage / Q000494:pharmacology*; D046790:Pancreas, Exocrine / Q000187:drug effects* / Q000378:metabolism; D010455:Peptides / Q000008:administration & dosage / Q000494:pharmacology*; D052336:Proglucagon / Q000008:administration & dosage / Q000494:pharmacology*; D017208:Rats, Wistar; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014688:Venoms / Q000008:administration & dosage / Q000494:pharmacology
chemical_list: D000199:Actins; D019394:Ki-67 Antigen; D053772:Oxyntomodulin; D010455:Peptides; D014688:Venoms; D052336:Proglucagon; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; D000077270:Exenatide; D000681:Amylases